MedTrace Logo

Study to Evaluate Benefits & Safety of Endourage Formula C™ Oral Drops in People With Post-Acute COVID-19 Syndrome.

NCT04828668 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 32

Last updated 2025-08-07

No results posted yet for this study

Summary

This study will explore the contribution of CBD oral drops in persons experiencing symptoms of Post Acute COVID Syndrome or "PACS".

Conditions

  • Covid 19

Interventions

DIETARY_SUPPLEMENT

Targeted Wellness Formula C™ Sublingual Drops - 1200mg - 30 mL (Formula C)

Hemp seed oil

Sponsors & Collaborators

  • Endourage, LLC

    lead INDUSTRY

Principal Investigators

  • Thomas P Young, PhD, NP · JOEL S ERICKSON, MD & THOMAS P YOUNG, PHD NP

Study Design

Allocation
RANDOMIZED
Purpose
OTHER
Masking
SINGLE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-04-02
Primary Completion
2022-01-31
Completion
2022-02-14

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04828668 on ClinicalTrials.gov